




RealRate

PHARMACEUTICAL 2014

Cytodyn Inc
Rank 212 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cytodyn Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cytodyn Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Cytodyn Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 90%, being 152% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	840
Cost of Goods Sold	0
Intangible Assets	3,317
Liabilities, Current	3,229
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	3,118
Other Liabilities	1,153
Other Net Income	374
Other Revenues	0
Property and Equipment	0
Research and Development	620
Selling, General and Administrative Expense	6,205

Output Variable	Value in 1000 USD
Assets	4,158
Liabilities	4,382
Expenses	9,942
Revenues	0
Stockholders Equity	-224
Net Income	-9,568
Comprehensive Net Income	-9,568
BaseVar	9,428
ECR before Limited Liability	-236%
Economic Capital Ratio	90%